COVID-19 Vaccine Timeline Expectations Have Become Unrealistic, Warns Porges
Herd Immunity Goal Could Be Years Away
Executive Summary
Despite record-breaking speed bringing several vaccine candidates into Phase I trials, the road ahead is likely to be much more treacherous and slow, warns one analyst.
You may also be interested in...
India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine
After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.